PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis

INTRODUCTION: Advanced biliary tract carcinoma (BTC) has a poor prognosis and few treatment options. We compared the efficacy of the PD-1 monoclonal antibody (PD-1-mAb) combined regimens with the standard chemotherapy in the first-line and second-line treatment of advanced BTC. METHODS: We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Wang, Feng-Hua, Sun, Kaiyu, Jiang, Chang, Peng, Sui, Xu, Li-Xia, Kuang, Ming, Guo, Gui-Fang, Chen, Shu-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635481/
https://www.ncbi.nlm.nih.gov/pubmed/36339826
http://dx.doi.org/10.2147/JIR.S364303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635481/
https://www.ncbi.nlm.nih.gov/pubmed/36339826
http://dx.doi.org/10.2147/JIR.S364303

Ejemplares similares